These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 661863)

  • 1. Hypotension associated with prekallikrein activator (Hageman-factor fragments) in plasma protein fraction.
    Alving BM; Hojima Y; Pisano JJ; Mason BL; Buckingham RE; Mozen MM; Finlayson JS
    N Engl J Med; 1978 Jul; 299(2):66-70. PubMed ID: 661863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paradoxical hypotension after volume expansion with plasma protein fraction.
    Colman RW
    N Engl J Med; 1978 Jul; 299(2):97-8. PubMed ID: 661869
    [No Abstract]   [Full Text] [Related]  

  • 3. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen.
    Revak SD; Cochrane CG; Griffin JH
    J Clin Invest; 1977 Jun; 59(6):1167-75. PubMed ID: 864009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypotensive effect of prekallikrein activator (PKA) in plasma protein fraction (PPF).
    Heinonen J; Peltola K; Himberg JJ; Suomela H
    Dev Biol Stand; 1980; 48():129-30. PubMed ID: 7024018
    [No Abstract]   [Full Text] [Related]  

  • 5. Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein.
    Meier HL; Pierce JV; Colman RW; Kaplan AP
    J Clin Invest; 1977 Jul; 60(1):18-31. PubMed ID: 874082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bradykinin-mediated hypotension after infusion of plasma-protein fraction.
    Van Rosevelt RF; Bakker JC; Sinclair DM; Damen J; Van Mourik JA
    J Lab Clin Med; 1982 Aug; 100(2):288-95. PubMed ID: 6980251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of various infusion media and solutions on the kallikrein-kinin system of human plasma].
    Dotsenko VL; Morozova NA; Iarovaia GA
    Vopr Med Khim; 1985; 31(4):116-21. PubMed ID: 3931350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prekallikrein activator levels and side effects with human albumin preparations.
    Lüben G; Quast U; Geiger H
    Dev Biol Stand; 1980; 48():123-7. PubMed ID: 6974110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prekallikrein activator (Hageman factor fragment) in human plasma fractions.
    Kuwahara SS
    Transfusion; 1980; 20(4):433-9. PubMed ID: 6773191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation.
    Weiss AS; Gallin JI; Kaplan AP
    J Clin Invest; 1974 Feb; 53(2):622-33. PubMed ID: 11344577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin.
    Kaplan AP; Austen KF
    J Exp Med; 1971 Apr; 133(4):696-712. PubMed ID: 4251126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of prekallikrein and high-molecular-weight kininogen in the contact activation of Hageman factor (factor XII) by sulfatides and other agents.
    España F; Ratnoff OD
    J Lab Clin Med; 1983 Oct; 102(4):487-99. PubMed ID: 6604770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hageman factor-dependent pathways: mechanism of initiation and bradykinin formation.
    Kaplan AP
    Fed Proc; 1983 Nov; 42(14):3123-7. PubMed ID: 6556144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of the function of Hageman factor fragments by high molecular weight kininogen.
    Liu CY; Scott CF; Bagdasarian A; Pierce JV; Kaplan AP; Colman RW
    J Clin Invest; 1977 Jul; 60(1):7-17. PubMed ID: 874091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An inhibitor from corn blocks the hypotensive action of plasma protein fraction and active Hageman factor.
    Marks E; Hojima Y; Frech ME; Keiser H; Pisano JJ
    Thromb Res; 1981 Jul 1-15; 23(1-2):97-102. PubMed ID: 6914060
    [No Abstract]   [Full Text] [Related]  

  • 16. Prekallikrein activator in human albumin.
    Paton CJ; Kerry PJ
    Lancet; 1981 Oct; 2(8249):747. PubMed ID: 6116876
    [No Abstract]   [Full Text] [Related]  

  • 17. Alteration of factor VII activity by activated Fletcher factor (a plasma kallikrein): a potential link between the intrinsic and extrinsic blood-clotting systems.
    Saito H; Ratnoff OD
    J Lab Clin Med; 1975 Mar; 85(3):405-15. PubMed ID: 234996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The assay of prekallikrein activator in human blood products.
    Snape TJ; Griffith D; Vallet L; Wesley ED
    Dev Biol Stand; 1979; 44():115-20. PubMed ID: 317467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma prekallikrein: quantitative determination by direct activation with Hageman factor fragment (beta-XIIa).
    Alving BM; Tankersley DL; Mason BL
    J Lab Clin Med; 1983 Feb; 101(2):226-41. PubMed ID: 6549773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiation of plasma prorenin activation by Hageman factor-dependent conversion of plasma prekallikrein to kallikrein.
    Sealey JE; Atlas SA; Laragh JH; Silverberg M; Kaplan AP
    Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5914-8. PubMed ID: 42905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.